November 14, 2011
SymBio Pharmaceuticals announced on November 10 that it has initiated domestic PII clinical trials of the anticancer agent bendamustine HCl (SyB L-0501) in first-line therapy for low-grade non-Hodgkin lymphoma and mantle cell lymphoma. The company is developing the drug in...read more